Shares in obesity drug maker soar on Wegovy trial 

Study showing weight-loss drug cuts risk of heart attacks and strokes by a fifth saw share surge of 17%

The increasingly popular Wegovy has transformed the weight-loss market since its US launch in June 2021, capturing the attention of patients, investors and celebrities worldwide. 

Novo Nordisk, the maker of Wegovy, has said a large study had shown the highly effective obesity treatment also had a clear cardiovascular benefit, boosting the Danish company's hopes of moving beyond its image as a lifestyle drug.

The increasingly popular Wegovy has transformed the weight-loss market since its US launch in June 2021, capturing the attention of patients, investors and celebrities worldwide.